Search

The article offers corporate profiles for clean-technology companies Sullivan Solar Power Inc., Genomatica Inc. and EDF Renewable Energy in San Diego, California. More than 80% of the revenue stream of EDF is from wind farms, but diversified into solar energy. Sullivan, which installs solar panels in rooftops, expects $34 million revenue for 2014 and $47 million in 2015. Genomatica has discovered a greener approach to manufacturing the industrial chemicals that finally turn into the plastics.

The article reports that biotechnology company Pfenex Inc. has filed for an initial public offering (IPO) to raise $74.8 million for the development of the drugs called biosimilars.

The article offers brief information on several health monitoring mobile device applications including the Cue for home-based diagnosis from Cue, the RevUp for remote monitoring and consultation from MD Revolution, and the Owaves app for wellness planning from Owaves Inc.

The article reports on the licensing deal by Ligand Pharmaceuticals Inc. with Viking Therapeutics Inc. which is concerned on the five drug development programs of Ligand. It mentions that Ligand also invested $2.5 million to Viking to advance Ligand's drug compounds. It also discusses the transformation of Ligand under the management of chief executive officer (CEO) John Higgins who took over the company in 2007.

The article focuses on the report from professional services firm PriceWaterhouseCoopers LLP which shows that venture capital (VC) investment in life sciences sector in San Diego, California is on the upswing due to the positive effects of biotechnological market. It says that 14 life sciences companies the the city received a total of $156 million in venture funding. The table which list the 14 life sciences companies which received venture funding in the first quarter of 2014 is presented.

The article focuses on the difficulty for nursing graduates to land a job despite shortage in the U.S. in 2014. It mentions that about 3% of graduates will obtain a job if health care system Scripps Health receives 5,000 applications. It notes that the difficulty is attributed to the recession and the health care industry's commitment to attract more students than what employers can accommodate. It also emphasizes that the competitive nursing market stirs Americans in making midcareer shifts.

The article reports that the plan of drugmaker Lumena Pharmaceuticals Inc. to raise $75 million in an initial public offering (IPO) will be ended with acquisition. It states that Irish drugmaker Shire PLC has agreed to pay $260 million for Lumena, a biotechnology firm in San Diego, California. It relates the statement of Lumena Chief Executive Officer (CEO) Mike Grey about the IPO and acquisition.

The article offers information regarding the plan of the drug manufacturer Ambrx Inc. to raise more than $86 million in an initial public offering in response to an erratic biotechnology market in 2014 and mentions various biotechnology companies in San Diego, California that trades on the market since May 2013, reflecting to the increase of stocks in the industry in 2013. Companies that were mentioned include Auspex Pharmaceuticals Inc., Receptos Inc., and Biocept Inc.

The article focuses on the success of Covered California which enrolled Latino population in the state-run health insurance exchange under the U.S. Patient Protection and Affordable Care Act. Topics include the increase of the marketing efforts to the Latino population in the first quarter of 2014, the increase of Latino enrollment in March 2014, and the growth of South Bay Health and Insurance Services by helping the underserved Latino population.

The article reports that biotherapeutic company Vital Therapies Inc. has raised lesser than it expected for its initial public offering in 2014.

The article focuses on the hair removal and care industry in San Diego, California. It features salons located in the area which offer hair care including Beauty By Dolly owned by Dolly Bakshai, Blink Lash Boutique owned by Janelle Koch, and Blow Pop Dry Bar owned by Mickel Bohi. Moreover, it states that the Beauty By Dolly salon can serve more than 20 customers per hour at low price.

The article discusses the performance of public companies in the biotechnology industry in San Diego, California. It presents the journal's list of the 50 largest local public companies, ranked by revenue in fiscal 2013 and the momentum built by the list which helped boost stock value across the board for city's life sciences companies. It mentions Quidel Corp., the second- highest revenue-generating public biotech in the region, and Sequenom Inc. which has shown marked change in 2014.

The article reports on the drug discovery company called Scripps Advance formed by the Scripps Research Institute to fast-track the translation of early-stage biomedical research into clinical development and commercialization.

The article reports on the surge of enrollment at the health insurance marketplace Covered California ended April 15, 2014. It mentions that signups in the marketplace amounted to 1.4 million which exceeded the initial estimates. It notes the decline in the number of small businesses enrolled in the Small Business Health Options Program of the exchange. It also emphasizes that about 77,000 San Diegans had signed up on the health exchange based on preliminary data from February 28, 2014.

The article reports on chemical firm Genomatica Inc. and its role in promoting biorenewable products in San Diego, California. It mentions that the lack of market for biofuels encourages flexibility in companies utilizing natural substances such as corn, discarded sugar cane fibers and algae. It also notes its acquisition of accolades and funds from investors in petroleum industries.

The article reports that a partnership with Tom Gephart, an old-school venture capitalist has been made by San Diego philanthropist Malin Burnham to launch a 200 million dollars "Cross-Border Innovation Fund," aiming to finance 10 to 20 startups.

The article features the Sirenas Marine Discovery Inc., a La Jolla-based biotechnology firm and its decision to dig the depths of the sea for a promising source of potential drugs in San Diego, California. The company was founded by Phil Baran, a scientist at The Scripps Research Institute. It notes that Baran politely turned down an offer for more cash when he was approached by potential investors after speaking at an event held by the Jewish Federation of San Diego County.

The article reports on a drug development rights deal between AnaptysBio Inc., a privately-held company focusing on cancer immunotherapy, and Tesaro Inc., a biopharmaceutical firm, which is worth $17 million.

The article reports that Chicago, Illinois private equity firm GTCR Golder Rauner LLC is investing up to $300 million to launch Maravai Life Sciences Inc. in San Diego, California, with former Gen-Prove Inc. executives Carl Hull and Eric Tardiff to head the acquisition-driven venture.

The article reports that Mark Stevenson, the president and chief operating officer (COO) of Life Technologies Corp., has assumed the role as president of the Life Sciences Solutions division of biotechnology company Thermo Fisher Scientific Inc. It discusses the formation of the company in 2008 through the merger between biotechnological companies Invitrogen Corp. and Applied Biosciences Inc. Moreover, Stevenson says that he holds people accountable without creating fear.

The article reports on the launch of a new company Human Longevity Inc. by scientist J. Craig Venter in San Diego, California.

The article reports on the partnership between San Diego, California-based Abide Therapeutics Inc. and biotechnological company Celgene Corp. to develop new drugs in inflammation immunology.

The article reports on the initiative of drug manufacturers to venture in generic drug market. It cites several pharmaceutical companies that go to the direction of generic market to bring in revenues such as Adamis Pharmaceuticals Corp., Santarus Inc., Somaxon Pharmaceuticals Inc. However, it indicates many generic drug makers can face generic litigation and can pose threat to the innovation and sales of companies that develop new medicines.

The article discusses the boundaries of North County, California ranging from the cities of Poway to the edges of Valley Center and Bonsall, as defined by San Diego North Economic Development Council. The region is showing its own growth from six key industries including biotechnology, information and communications technology, and connected tourism. It also notes the addition of three acres to the water park of Legoland California Resort located in the city of Carlsbad.

The article reports on the acquisition of Cadence Pharmaceuticals Inc., a pharmaceutical company based in San Diego, California for $1.3 billion by Mallinckrodt PLC, an Irish specialty drug manufacturer.

The article discusses the economic trends of monitoring devices from DexCom Inc., a company that manufactures, and distributes continuous glucose monitoring systems for diabetes management. It mentions that DexCom is one of the most highly valued medical device manufacturer in San Diego, California. It notes that the monitoring devices of DexCom has been approved by the Food and Drug Administration (FDA) in the U.S.

The article reports on the expansion of San Diego, California-based commercial health plan Sharp Health Plan of its market share in the individual market in the region. It is inferred that Sharp Heath Plan has enrolled 5,200 residents by the end of January 2013, from 4,126 by the end of the previous month. Information about the condition of other insurers participating in the health insurance exchange Covered California are offered.

An interview with Tri-City Medical Center interim-chief executive officer Casey Fatch is presented. Fatch talks about the financial performance of the center as well as discusses the impact of Tri-City's advertising on its patient flow. He explains the expenses he incurs for physician recruitment dinners, emphasizing its significance in helping the medical center grow. Fatch also tackles the transparency of and united leadership of Tri-City.

The article reports that chief executive officer (CEO) David Wellis of San Diego Blood Bank seek to diversify revenue due to the decline of donor rates.

The article reports on the acquisition of the life sciences software company Accelrys Inc. by software design company Dassault Systèmes SA.

The article reports on the financial growth of genome sequencing equipment maker Illumina Inc. in 2014. Topics discussed include the revenue growth of the company in 2013, the upgrade of the price target of JP Morgan analyst Tycho Peterson for Illumina, and the acquisition of the company of the prenatal diagnostics firm Verinata Health Inc.

The article announces that David Gollaher and Holly Smithson resigned as chief executive officer at biotechnology advocacy group California Health Institute and chief operating officer at clean technology organization Clean Tech San Diego respectively.

The article reports on the divestment of assets of Ireland-based pharmaceutical firm Shire PLC's San Diego, California-based business Dermagraft, which led to the end of an initially promising tenure in the city, due to a ruling on medicare that reduced reimbursement for wound care products.

The article reports on the $117.4 million raised by biopharmaceutical company Receptos Inc in its secondary public offering, which will be used to finance clinical trials of its multiple sclerosis and ulcerative colitis drugs, as well as for general corporate purposes in San Diego, California.

The article reports on the acquisition of a San Diego, California-based stem cell firm, Medistem Inc., by a Germantown, Maryland-based synthetic biology company, Intrexon Corp. for about $26 million. The ability and potency of Medistem's endometrial regenerative cells will be expanded by the genetic engineering capabilities of Intrexon, according to Alan Lewis of Medistem. Medistem's stockholders will receive 27 cents in exchange for each share of Medistem common stock in cash.

The article provides an overview of the health care industry in the U.S. in 2014. It highlights the impact of the Affordable Care Act on the sector across the country and the move of providers and consumers to adjust to the new norm of a wildly changed health economy. Information about consolidation in the industry is also provided.

The article focuses on the 57% increase brought by the implementation of Affordable Care Act (ACA) to the rates of health insurance premiums. It discusses the troubles experienced by Christian Wheeler Engineering human resource manager Lynette Lampton of either renewing the company insurance in 2014 or finding other alternatives. It states that the ACA is not considerable the major reason which causes small businesses to drop insurance coverage for employees.

The article offers information on medical information technology which will help in cutting health care costs in 2014 in San Diego, California. It mentions that mobile health, including Bluetootth-enabled health trackers, location-aware telemonitoring systems, and wireless monitoring of vital signs, will be the biggest health care trend in 2014. It notes that telemedicine uses information and telecommunication technology to offer clinical health care at a distance.

The article offers information on the joint venture of British pharmaceutical company GlaxoSmithKline (GSK) and Avalon Ventures, a firm based in La Jolla in San Diego, California, to launch a startup called Sitari Pharmaceuticals Inc. which will focus on celiac disease treatment.

The article reports on the program planned by the city of San Diego, California in cooperation with the utility firm San Diego Gas & Electric, the nonprofit organization CleanTech San Diego, and possibly with the semiconductor company Qualcomm Inc. to reduce electric expenditures.

The article focuses on Irish drugmaker Shire PLC which has constructed a regenerative medicine building in Sorrento Mesa, California for its Dermagraft production. It states that the sales of Dermagraft, a diabetic foot ulcer treatment, has been declining by $64.7 million sales from January-September 2013. According to Flemming Ornskov of Shire PLC, the firm is planning to discontinue the manufacturing facility in Sorrento Mesa in order to help reduce their losses.

The article reports on the plan of San Diego, California-based company BioMed Realty Trust Inc. to increase its venture funding, high-profiles acquisitions, and public stock offerings in the life-sciences industry with a new campus for University Towne Center (UTC).

The article reports on the plan of pharmaceutical company Zogenix Inc. to use the proceeds from its public offering to launch its Zohydro narcotic painkiller and increase sales force. Chief executive officer (CEO) Roger Hawley mentions the addition of 100 drug representatives in the U.S. Information regarding expansion plans of the company is also discussed.

The article focuses on the development on the regenerative medicine field in San Diego, California. It says that the sector has been raised with the $100 million grant by businessman T. Denny Sanford to he University of California, San Diego to set up a center for stem cell therapy research. It cites several regenerative medicine firms in the city including MediStem Inc., Cytori Therapeutics Inc., and International Stem Cell Corp.

The article focuses on San Diego, California-based equity company DJO Global Inc. owned by the equity company Blackstone Group LP. It mentions that DJO is focused on manufacturing knee braces for football players. It adds that the $1.1 billion company is on the rapid growth and is realigning itself from a sports medicine company to one focused on pain management devices.

The article reports that the Tri-City Medical Center in North County, California is regrouping after the termination of its chief executive, Larry Anderson, with chief operating officer Casey Fatch who file the position in the interim, however, it is also focusing on its stakeholder's experiences.

The article discusses the telemedicine program called MDLive launched by San Diego, California-based nonprofit health system Scripps Health that could allow its employees to consult doctors remotely.

The article reports on the expansion of San Francisco, California-based Genentech Inc. It states that the pharmaceutical company will invest in its Oceanside plant, with the expected construction in the first quarter of 2014 and expected completion in 2016. It relates the plan of Genentech to hire 50 scientists, engineers and technicians to support its expanded operations.

The article reports that Celladon Corp. and Vital Therapies Inc. of San Diego, California have filed to go initial public offerings (IPO) with aims to raise $86.3 million. It relates the plan of Vital Therapies to use the proceeds of its IPO to further finance three Phase-3 clinical studies of its Elad medical device. On the other hand, Celladon plans to use the IPO funding in expanding clinical trials for its heart failure gene therapy.

The article reports on the low sales performance of anti-obesity prescription pills from Arena Pharmaceuticals Inc. and Vivus Inc. in California. According to analysts, the sales of Arena's Belviq and Vivus' Qsymia are slow and forced them to downgrade revenues estimates for the pills. It also discusses the financial performance of both pharmaceutical companies.